Quarterly report [Sections 13 or 15(d)]

Consolidated Balance Sheets (Unaudited)

v3.25.3
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 11,002 $ 24,125
Accounts receivable 448  
Inventory 1,149  
Income taxes receivable 0 48
Prepaid expenses and other current assets 1,128 614
Total current assets 13,727 24,787
Intangible asset, net 18,710 19,746
Property and equipment, net 18 23
Restricted cash 29 34
Other assets 19 5
Total assets 32,503 44,595
Current liabilities:    
Accounts payable 577 251
Accrued expenses 5,216 2,651
Exchangeable notes 0 14,463
Royalty-linked notes 281  
Income taxes payable 24  
Other current liabilities 332 240
Total current liabilities 6,430 17,605
Pfizer promissory note 21,215 20,300
Royalty-linked notes 12,239 10,771
Total liabilities 39,884 48,676
Commitments and contingencies (Note 17)
Shareholders' deficit    
Undesignated preferred shares, $0.01 par value per share: 100,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued at September 30, 2025 and December 31, 2024
Ordinary shares, $0.01 par value per share: 80,000,000 shares authorized at September 30, 2025 and December 31, 2024, 48,991,860 shares issued at September 30, 2025; 31,534,233 shares issued at December 31, 2024 490 315
Additional Paid in Capital 498,580 481,676
Accumulated deficit (506,451) (486,072)
Total shareholders' deficit (7,381) (4,081)
Total liabilities and shareholders' deficit $ 32,503 $ 44,595